GE Healthcare and Theragnostics are to collaborate on a new Prostate-Specific Membrane Antigen PET/CT imaging agent whereby the former will lead all pre-approval commercial preparations and all subsequent commercial and distribution activities upon approval. The latter will lead the development of the tracer, GalliProst, and has phase two clinical study data showing it met its primary and secondary endpoints. It showed that one third of newly diagnosed prostate cancer patients, and more than half of patients with biochemically recurrent disease, had their treatment plans modified as a result of a GalliProst scan. Patient management changes went up to 75% in a post-radical radiotherapy setting.
Theragnostics’ chief executive officer, Greg Mullen, said: "This agreement is validation of the potential for our novel prostate cancer Gallium-68 diagnostic tracer GalliProst which can benefit the treatment of prostate cancer patients around the globe. We are very pleased to sign our second agreement with GE Healthcare following our agreement last year for a diagnostic tracer for imaging kidney function and scarring."
“GE Healthcare and Theragnostics partner on GalliProst for Prostate Cancer“
GE Healthcare's Global Product Leader, Molecular Imaging Oncology, Pharmaceutical Diagnostics business, Sanka Thiru, said: "We are excited to partner with Theragnostics on GalliProst to give vital insights into prostate cancer. We believe that this partnership enables both parties to leverage each other's key areas of expertise in order to accelerate the development of GalliProst and ultimately improve patient care."